Mechanism-driven phase i translational study of trifluoperazine in adults with sickle cell disease

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 419-424

  Molokie, Robert E ^a,b,c,d   Wilkie, Diana J ^c,d   Wittert, Harriett ^c   Suarez, Marie L ^c   Yao, Yingwei ^c   Zhao, Zhongsheng ^c   He, Ying ^c   Wang, Zaijie J ^c,d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

Neuropathic pain; Phase 1 study; Safety; Sickle cell disease; Trifluoperazine

Indexed keywords

NEUROPATHIC PAIN; PHASE 1 STUDY; SAFETY; SICKLE CELL DISEASE; TRIFLUOPERAZINE;

ADULT; ANALGESICS; ANEMIA, SICKLE CELL; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; TRIFLUOPERAZINE; YOUNG ADULT;

EID: 84893743019     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.10.062     Document Type: Article

References (41)

1. F. Benedetti, A. Pollo, L. Lopiano, M. Lanotte, S. Vighetti, and I. Rainero Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses J. Neurosci. 23 2003 4315 4323 (Pubitemid 36958452)
2. D.C. Brousseau, P.L. Owens, A.L. Mosso, J.A. Panepinto, and C.A. Steiner Acute care utilization and rehospitalizations for sickle cell disease JAMA 303 2010 1288 1294
3. 2+/calmodulin-dependent protein kinase II reverses experimental neuropathic pain in mice J. Pharmacol. Exp. Ther. 330 2009 650 659
4. 2+/calmodulin-dependent protein kinase II alpha is required for the initiation and maintenance of opioid-induced hyperalgesia J. Neurosci. 30 2010 38 46
5. G. Chouinard, and H.C. Margolese Manual for the Extrapyramidal Symptom Rating Scale (ESRS) Schizophr. Res. 76 2005 247 265 (Pubitemid 40804771)
6. C. Dampier, B. Ely, D. Brodecki, and P. O'Neal Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports J. Pain 3 2002 461 470 (Pubitemid 35462622)
7. C. Dampier, E. Ely, D. Brodecki, and P. O'Neal Home management of pain in sickle cell disease: a daily diary study in children and adolescents J. Pediatr. Hematol. Oncol. 24 2002 643 647 (Pubitemid 35285103)
8. Ezenwa, M.O., Molokie, R.E., Wang, Z.J., Yao, Y., Suarez, M.L., Pullum, C., Fillingim, R.B., Wilkie, D.J., Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic pain (in review).
9. C. Ferte, J.C. Soria, and N. Penel Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials PloS One 6 2011 e16633
10. 2+/calmodulin-dependent kinase kinase alpha is expressed by monocytic cells and regulates the activation profile PloS One 3 2008 e1606
11. P. Heller Hemoglobinopathic dysfunction of the red cell Am. J. Med. 41 1966 799 814
12. E.C. Huskisson Visual analogue scales R. Melzack, Pain Assessment and Management 1983 Raven press New York 33 37
13. R.N. Jamison, R.H. Gracely, S.A. Raymond, J.G. Levine, B. Marino, T.J. Herrmann, M. Daly, D. Fram, and N.P. Katz Comparative study of electronic vs. paper VAS ratings: a randomized, crossover trial using healthy volunteers Pain 99 2002 341 347 (Pubitemid 35247557)
14. A. Jaszczyszyn, K. Gasiorowski, P. Swiatek, W. Malinka, K. Cieslik-Boczula, J. Petrus, and B. Czarnik-Matusewicz Chemical structure of phenothiazines and their biological activity Pharmacol. Rep. 64 2012 16 23
15. E. Kremer, J.H. Atkinson, and R.J. Ignelzi Measurement of pain: patient preference does not confound pain measurement Pain 10 1981 241 248 (Pubitemid 11096921)
16. E. Kremer, and J.H. Atkinson Jr. Pain measurement: construct validity of the affective dimension of the McGill Pain Questionnaire with chronic benign pain patients Pain 11 1981 93 100 (Pubitemid 11047025)
17. S. Lanzkron, C.P. Carroll, and C. Haywood Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database Am. J. Hematol. 85 2010 797 799
18. 2+/calmodulin-dependent protein kinase II J. Pharmacol. Exp. Ther. 325 2008 267 275 (Pubitemid 351439181)
19. A. Mahmood A double-blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia Br. J. Haematol. 16 1969 181 184
20. V.E. Maikler, M.E. Broome, P. Bailey, and G. Lea Childrens' and adolescents' use of diaries for sickle cell pain J. Soc. Pediatr. Nurs. 6 2001 161 169
21. Marques, L.O., Lima, M.S., Soares, B.G., 2004. Trifluoperazine for Schizophrenia. Cochrane Database Syst. Rev., CD003545.
22. R.E. Molokie, Z.J. Wang, and D.J. Wilkie Presence of neuropathic pain as an underlying mechanism for pain associated with cold weather in patients with sickle cell disease Med. Hypotheses 77 2011 491 493
23. M.J. Ohlow, and B. Moosmann Phenothiazine: the seven lives of pharmacology's first lead structure Drug Discov. Today 16 2011 119 131
24. F.B. Piel, A.P. Patil, R.E. Howes, O.A. Nyangiri, P.W. Gething, M. Dewi, W.H. Temperley, T.N. Williams, D.J. Weatherall, and S.I. Hay Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates Lancet 381 2013 142 151
25. O.S. Platt, D.J. Brambilla, W.F. Rosse, P.F. Milner, O. Castro, M.H. Steinberg, and P.P. Klug Mortality in sickle cell disease. Life expectancy and risk factors for early death N. Engl. J. Med. 330 1994 1639 1644
26. O.S. Platt, B.D. Thorington, D.J. Brambilla, P.F. Milner, W.F. Rosse, E. Vichinsky, and T.R. Kinney Pain in sickle cell disease. Rates and risk factors N. Engl. J. Med. 325 1991 11 16
27. A.B. Raper A commentary on the anti-sickling effect of the phenothiazine drugs Trans. R. Soc. Trop. Med. Hyg. 62 1968 84 91
28. J. Scott, and E.C. Huskisson Vertical or horizontal visual analogue scales Ann. Rheum. Dis. 38 1979 560 (Pubitemid 10219287)
29. G.R. Serjeant The painful crisis G.R. Serjeant, The Clinical Features of Sickle Cell Disease 1974 North-Holland Publishing Company New York 137 146
30. B.S. Shapiro, D.F. Dinges, E.C. Orne, N. Bauer, L.B. Reilly, W.G. Whitehouse, K. Ohene-Frempong, and M.T. Orne Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance Pain 61 1995 139 144
31. W.R. Smith, L.T. Penberthy, V.E. Bovbjerg, D.K. McClish, J.D. Roberts, B. Dahman, I.P. Aisiku, J.L. Levenson, and S.D. Roseff Daily assessment of pain in adults with sickle cell disease Ann. Intern. Med. 148 2008 94 101 (Pubitemid 351651552)
32. G. Sudeshna, and K. Parimal Multiple non-psychiatric effects of phenothiazines: a review Eur. J. Pharmacol. 648 2010 6 14
33. L. Tang, P.K. Shukla, and Z.J. Wang Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance Neurosci. Lett. 397 2006 1 4 (Pubitemid 43340448)
34. C.A. von Hehn, R. Baron, and C.J. Woolf Deconstructing the neuropathic pain phenotype to reveal neural mechanisms Neuron 73 2012 638 652
35. Z.J. Wang, D.J. Wilkie, and R. Molokie Neurobiological mechanisms of pain in sickle cell disease Hematol Am. Soc. Hematol. Educ. Program. 2010 2010 403 408
36. D. Wilkie, N. Lovejoy, M. Dodd, and M. Tesler Cancer pain intensity measurement: concurrent validity of three tools - finger dynamometer, pain intensity number scale, visual analogue scale Hospice J. 6 1990 1 13 (Pubitemid 20293260)
37. D.J. Wilkie, M.K. Judge, D.L. Berry, J. Dell, S. Zong, and R. Gilespie Usability of a computerized PAINReportIt in the general public with pain and people with cancer pain J. Pain Symptom Manage. 25 2003 213 224 (Pubitemid 36287080)
38. D.J. Wilkie, R. Molokie, D. Boyd-Seal, M.L. Suarez, Y.O. Kim, S. Zong, H. Wittert, Z. Zhao, Y. Saunthararajah, and Z.J. Wang Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease J. Natl. Med. Assoc. 102 2010 18 27
39. T.N. Williams, and D.J. Weatherall World distribution, population genetics, and health burden of the hemoglobinopathies Cold Spring Harb. Perspect. Med. 2 2012 a011692
40. C.J. Woolf Evidence for a central component of post-injury pain hypersensitivity Nature 306 1983 686 688 (Pubitemid 14201852)
41. C. Yang, Y. Chen, L. Tang, and Z.J. Wang Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence J. Pharmacol. Exp. Ther. 338 2011 164 172